Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

NEUROCUPLE™ som et opioidalternativ etter total kneproteseoperasjon

10. november 2026 oppdatert av: Jacques E. Chelly

Rollen til NEUROCUPLE™ som et alternativ til opioider hos pasienter etter total kneprotesekirurgi

The goal of this clinical trial is to learn if the NEUROCUPLE device can reduce pain and opioid use after primary unilateral total knee arthroplasty (TKA) in adults.

The main questions it aims to answer are:

  • Does the NEUROCUPLE device reduce postoperative pain at rest during the first 24 hours after TKA?
  • Does the NEUROCUPLE device reduce opioid consumption during the first 24 hours after TKA?

Researchers will compare the NEUROCUPLE device to a placebo device (identical in appearance but inactive) to see if the device reduces pain and opioid use after surgery.

Participants will:

  • Apply the NEUROCUPLE device or placebo device for 7 days following surgery
  • Have their pain and opioid use monitored through clinical records and patient reporting
  • Report pain at rest and during movement on postoperative Days 2 and 7
  • Be assessed for nausea, vomiting, device-related side effects, length of hospital stay, and overall satisfaction

Studieoversikt

Studietype

Intervensjonell

Registrering (Antatt)

274

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studer Kontakt Backup

  • Navn: Heather Margonari, DNP, FNP, BC
  • Telefonnummer: 412-623-1914
  • E-post: margonarih@upmc.edu

Studiesteder

    • Pennsylvania
      • Pittsburgh, Pennsylvania, Forente stater, 15232
        • UPMC Shadyside Hospital
        • Hovedetterforsker:
          • Jacques E. Chelly, MD, PhD, MBA
        • Ta kontakt med:
        • Ta kontakt med:
      • Pittsburgh, Pennsylvania, Forente stater, 15237
        • UPMC Passavant Hospital
        • Hovedetterforsker:
          • Jacques E. Chelly, MD, PhD, MBA
      • Pittsburgh, Pennsylvania, Forente stater, 15146
        • UPMC East Hospital
        • Hovedetterforsker:
          • Jacques E. Chelly, MD, PhD, MBA

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • >18 years of age
  • Scheduled for elective primary unilateral TKA

Exclusion Criteria:

  • Children (<18 yr.)
  • Pregnant women
  • Active alcoholism (defined as daily use of more than 1 liter of wine and /or 3 or more shots of hard liquor) or drug abuse (defined as daily use of illicit drugs)
  • Severe chronic pain condition that requires daily preoperative opioid dependence
  • Other concomitant surgery being performed in addition to TKA
  • Patients undergoing bilateral TKA
  • Patients undergoing knee replacement revision
  • Patients with limited mobility (in a wheelchair or requiring a walker)
  • Patients who are not returning home after surgery

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Dobbelt

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: NEUROCUPLE™ Group

This arm of subjects will receive the active NEUROCUPLE™ patch to wear for 7 days following their TKA surgery.

nCAP Medical has developed an effective, safe, non-opioid alternative, the NEUROCUPLE™ device, based on an innovative nanotechnology to reduce surgical pain and facilitate functional recovery while reducing opioid prescriptions, opioid-related adverse events and reducing the cost of care in millions of Americans undergoing TKA each year. The patch will be worn for 7-days

Participants in both arms will receive approved Enhanced Recovery After Surgery (ERAS) multimodal care, including preoperative education and optimization, intraoperative minimally invasive techniques and multimodal analgesia, and postoperative early mobilization, early nutrition, pain control, and monitoring for complications

Sham-komparator: Sham Group

This arm of subjects will receive the placebo (non-active, sham) patch to wear for 7 days following their TKA surgery.

Participants in both arms will receive approved Enhanced Recovery After Surgery (ERAS) multimodal care, including preoperative education and optimization, intraoperative minimally invasive techniques and multimodal analgesia, and postoperative early mobilization, early nutrition, pain control, and monitoring for complications

Non-active placebo patch visually identical to NEUROCUPLE™ worn for 7 days following total knee arthroplasty.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Opioid Consumption
Tidsramme: 0- 24 hours post-surgery

Total opioid consumption, expressed in milligrams of morphine equivalents (MME), during the first 24 hours following surgery.

Opioid use will be calculated using all available data sources, including in-hospital medication administration records and, when applicable, the state Prescription Drug Monitoring Program (PDMP).

MME values will be compared between the NEUROCUPLE™ patch group and the placebo patch group. Lower MME values indicate reduced opioid requirements and may reflect improved postoperative pain control, while higher MME values suggest increased opioid use and potentially greater pain or slower recovery.

0- 24 hours post-surgery
Pain at Rest Using Numerical Rating Scale (NRS)
Tidsramme: 0-24 hours post-surgery

Pain at rest during the first 24 hours after surgery will be assessed using a Numerical Rating Scale (NRS; 0 = no pain, 10 = worst pain) and compared between the NEUROCUPLE™ patch group and the placebo patch group. Higher scores indicate worse pain

0-24 hours post-surgery

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Pain Scores Using Numerical Rating Scale (NRS) at Rest and during Movement
Tidsramme: Post-operative at Day 2 and Day 7

Pain will be assessed using a Numerical Rating Scale (0 = no pain, 10 = worst pain) at rest and during movement on postoperative Days 2 and 7. Higher scores indicate worse pain.

Post-operative at Day 2 and Day 7
Patient Satisfaction
Tidsramme: at Post-operative Day 7

Patient satisfaction with recovery and device use will be assessed on postoperative Day 7 using standardized questionnaires. Scores range from 0 to 10, where 0 indicates the lowest level of satisfaction and 10 indicates the highest.

at Post-operative Day 7
Opioid Consumption
Tidsramme: Post-Operative Day 0- Day 7

Total opioid consumption, expressed in milligrams of morphine equivalents (MME), will be recorded over the 7-day postoperative period.

Opioid use will be calculated using all available data sources, including in-hospital medication administration records and the state Prescription Drug Monitoring Program (PDMP) when applicable.

MME values will be compared between the NEUROCUPLE™ patch group and the placebo patch group. Lower MME values indicate reduced opioid requirements and may reflect improved postoperative pain control, whereas higher MME values suggest increased opioid use and potentially greater pain or slower recovery.

Post-Operative Day 0- Day 7
Postoperative Adverse Events and Device-Related Side Effects
Tidsramme: Postoperative Days 0-7

The incidence of postoperative adverse events, including any events determined to be related to the study device, will be recorded and compared between the treatment groups during the 7-day postoperative period.

Lower incidence rates indicate fewer complications and a more favorable safety profile, whereas higher incidence rates suggest increased complications, potential device-related issues, or a less favorable safety profile.

Postoperative Days 0-7
Incidence of postoperative nausea and/or vomiting (yes/no)
Tidsramme: Postoperative Days 0-7

Incidence and severity of postoperative nausea and vomiting will be recorded over the 7-day postoperative period as (yes/no) and compared between groups.

Postoperative Days 0-7
Postoperative Length of Stay
Tidsramme: From the date of surgery until hospital discharge (within the 7-day study period)

Length of hospital stay, defined as the number of days from the date of surgery to the date of hospital discharge, will be recorded and compared between groups.

Lower length of stay values indicate faster recovery, fewer complications, and earlier readiness for discharge. Higher length of stay values suggest slower recovery, increased complications, or higher postoperative symptom burden.

From the date of surgery until hospital discharge (within the 7-day study period)

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Samarbeidspartnere

Etterforskere

  • Hovedetterforsker: Jacques E. Chelly, MD, PhD, MBA, University of Pittsburgh / UPMC
  • Studieleder: Alisha Maslanka, BS, CCRC, University of Pittsburgh / UPMC
  • Studieleder: Heather Margonari,, University of Pittsburgh / UPMC

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

1. desember 2026

Primær fullføring (Antatt)

1. august 2027

Studiet fullført (Antatt)

1. november 2027

Datoer for studieregistrering

Først innsendt

23. februar 2026

Først innsendt som oppfylte QC-kriteriene

23. februar 2026

Først lagt ut (Faktiske)

27. februar 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

12. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

10. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Ja

produkt produsert i og eksportert fra USA

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere